Surgery for Recurrent Intrahepatic Cholangiocarcinoma

Status Completed

Clinical Trial Summary

The investigators retrospectively reviewed the participants suffering from recurrent intrahepatic cholangiocarcinoma after curative resection and aimed to explore the predictive factors for recurrence and clarify the potential benefit of repeat hepatectomy or/with metastasectomy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04072250
Study type	Observational
Source	Chang Gung Memorial Hospital
Contact
Status	Completed
Phase
Start date	June 1, 2017
Completion date	October 30, 2018

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04077983` - Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma	Phase 2
Not yet recruiting	`NCT04527679` - Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma	Phase 2
Terminated	`NCT03267940` - Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma	Phase 1
Recruiting	`NCT04634058` - PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment	Phase 2
Active, not recruiting	`NCT03951597` - Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma	Phase 2
Completed	`NCT03377179` - A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma	Phase 2
Active, not recruiting	`NCT04361331` - Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma	Phase 2
Recruiting	`NCT05210322` - Percutaneous Cholangiopancreatoscopy Registry
Recruiting	`NCT04782804` - Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence	Phase 1/Phase 2
Recruiting	`NCT04264260` - Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment	Phase 2
Recruiting	`NCT06140134` - Liver Transplantation in Intrahepatic Cholangiocarcinoma
Enrolling by invitation	`NCT04195503` - Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma	N/A
Recruiting	`NCT04506281` - PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors	Phase 2
Recruiting	`NCT05124002` - Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma	Phase 4
Terminated	`NCT03316222` - Study of GNS561 in Patients With Liver Cancer	Phase 1/Phase 2
Completed	`NCT03405909` - Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study
Available	`NCT03414489` - Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)